266 related articles for article (PubMed ID: 1351321)
1. Neonatal 6-OHDA lesions differentially affect striatal D1 and D2 receptors.
Neal BS; Joyce JN
Synapse; 1992 May; 11(1):35-46. PubMed ID: 1351321
[TBL] [Abstract][Full Text] [Related]
2. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Neal-Beliveau BS; Joyce JN
Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
[TBL] [Abstract][Full Text] [Related]
3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
4. Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat.
Simson PE; Johnson KB; Jurevics HA; Criswell HE; Napier TC; Duncan GE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Dec; 263(3):1454-63. PubMed ID: 1361576
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development.
Neal BS; Joyce JN
Brain Res Dev Brain Res; 1991 Jun; 60(2):105-13. PubMed ID: 1832593
[TBL] [Abstract][Full Text] [Related]
6. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
7. Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model.
Lawler CP; Gilmore JH; Watts VJ; Walker QD; Southerland SB; Cook LL; Mathis CA; Mailman RB
Synapse; 1995 Dec; 21(4):299-311. PubMed ID: 8869160
[TBL] [Abstract][Full Text] [Related]
8. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 1. Dopaminergic neurons and receptors.
Yokoyama C; Okamura H
J Pharmacol Exp Ther; 1997 Feb; 280(2):1016-30. PubMed ID: 9023319
[TBL] [Abstract][Full Text] [Related]
9. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
10. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
11. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
12. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
McPherson RJ; Marshall JF
Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
[TBL] [Abstract][Full Text] [Related]
13. Comparative development of D1-dopamine and mu opiate receptors in normal and in 6-hydroxydopamine-lesioned neonatal rat striatum: dopaminergic fibers regulate mu but not D1 receptor distribution.
Caboche J; Rogard M; Besson MJ
Brain Res Dev Brain Res; 1991 Jan; 58(1):111-22. PubMed ID: 1849802
[TBL] [Abstract][Full Text] [Related]
14. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
Hu XT; Wachtel SR; Galloway MP; White FJ
J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
[TBL] [Abstract][Full Text] [Related]
15. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
Frohna PA; Rothblat DS; Joyce JN; Schneider JS
Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
[TBL] [Abstract][Full Text] [Related]
16. There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum.
Thomas WS; Neal-Beliveau BS; Joyce JN
Brain Res Dev Brain Res; 1998 Nov; 111(1):99-106. PubMed ID: 9804909
[TBL] [Abstract][Full Text] [Related]
17. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment.
Joyce JN
Exp Neurol; 1991 Sep; 113(3):277-90. PubMed ID: 1833220
[TBL] [Abstract][Full Text] [Related]
18. Limbic pallidal adaptations following long-term cessation of dopaminergic transmission: lack of upregulation of dopamine receptor function.
Heidenreich BA; Mitrovic I; Battaglia G; Napier TC
Exp Neurol; 2004 Apr; 186(2):145-57. PubMed ID: 15026253
[TBL] [Abstract][Full Text] [Related]
19. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.
Criswell HE; Johnson KB; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756
[TBL] [Abstract][Full Text] [Related]
20. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
